Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Contemporary art collage. Human hand taking off book symbolizing growth of professional skills and knowledges. Education. Concept of business, office, career, creativity, growth, achievement, ad

Mergers & acquisitions

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in CNS.” Supernus’ offer beats Biogen’s unsolicited bid of about $7.22 per share, which arrived with a thud in late January.

June 16, 2025

2 min read

Annalee Armstrong

Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson

Cell therapy

J&J’s Dual-Targeting CAR T Hits 80% Complete Response in Early Lymphoma Study

Analysts at Truist Securities called J&J’s CAR T readout “compelling,” noting that the efficacy figures could position the cell therapy as a formidable competitor to the current standard of care, Gilead’s Yescarta.

June 16, 2025

2 min read

Tristan Manalac

Government

Makary Considers More Cuts at FDA Amid Continued Delays

According to an internal email, the agency may be in for more consolidation in areas including human resources, communications, travel and acquisitions.

June 16, 2025

1 min read

Tristan Manalac

Biotechnology and molecular genetic engineering. 3D illustration of science and molecular technology.

Duchenne muscular dystrophy

UPDATE: Second Patient Dies After Receiving Sarepta’s DMD Gene Therapy Elevidys

Sarepta’s shares crashed 41% in premarket trading Monday morning to $21.01 after the biotech reported a second death from acute liver failure, a known side effect of adeno-associated virus-based gene therapies.

June 16, 2025

3 min read

Tristan Manalac

Sponsored

Taipei City Government Partners With Six Biotech Companies to Showcase at BIO International Convention 2025

The 2025 BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S. time) at the Boston Convention & Exhibition Center. This year, Taipei City Government is partnering with six Taipei-based biotech companies, including PanCAD.ai Co., Ltd., Instant NanoBiosensors Co., Ltd., Bened Biomedical Co., Ltd., Cancer Free Biotech Ltd., Xantho Biotechnology Co., Ltd., and Energenesis Biomedical Co., Ltd., to showcase their innovations at the Taiwan Pavilion (Booth #1645) in the Taipei Exhibition Area.

June 16, 2025

5 min read

AI robot with cancer cells and virus. 3d illustration

Artificial intelligence

As AI Dawns in Precision Oncology, 2025 Expected To Be a ‘Turning Point’

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential efficacy and safety profiles of their molecules and synthesize massive multi-omic information to gain a more complete understanding of challenging cancers.

June 16, 2025

9 min read

Tristan Manalac

Pictured: European flags flap in the wind outside

Opinion

US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe

While cancelled NIH grants and regulatory uncertainty are less hospitable to clinical research in the U.S., Europe must play its cards right to attract more studies.

June 16, 2025

6 min read

Craig Koch

RSV

Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology

Later this month, HHS Secretary Robert F. Kennedy Jr.'s revamped CDC vaccine advisory committee will discuss RSV vaccination guidelines for the newly approved patient group, high-risk adults 18 through 49. Analysts and other experts have warned that the new panel includes some who have documented anti-vaccine sentiments as well as those who have spoken out against mRNA technology specifically.

June 13, 2025

2 min read

Tristan Manalac